ArticleJournal of virology2023
Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
Open access · hybridAbstract read
In one paragraph
Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.Journal of virology · 2025Article
- Review
- SGV-caller: SARS-CoV-2 genome variation caller.Heliyon · 2025Article
- Using minor variant genomes and machine learning to study the genome biology of SARS-CoV-2 over time.Nucleic acids research · 2025Article
- Article
- Article
- Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants.mBio · 2024Review
- Article
- Article
- Generation of recombinant viruses directly from clinical specimens of COVID-19 patients.Journal of clinical microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 17 institutions in 4 countries.
Izumi Kimura *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.
Daichi Yamasoba *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.
Hesham Nasser *Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University , Kumamoto, Japan.
Hayato Ito *Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University , Sapporo, Japan.
Jiri Zahradnik *Department of Biomolecular Sciences, Weizmann Institute of Science , Rehovot, Israel.
Jiaqi Wu *Department of Molecular Life Science, Tokai University School of Medicine , Isehara, Japan.
Shigeru Fujita *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.
Keiya Uriu *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.
Jiei SasakiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University , Kyoto, Japan.
Tomokazu TamuraDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University , Sapporo, Japan.ORCID 0000-0003-1395-6610
Rigel SuzukiDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University , Sapporo, Japan.
Sayaka DeguchiCenter for iPS Cell Research and Application (CiRA), Kyoto University , Kyoto, Japan.
Arnon PlianchaisukDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.
Kumiko YoshimatsuInstitute for Genetic Medicine, Hokkaido University , Sapporo, Japan.
Yasuhiro KazumaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University , Kyoto, Japan.
Shuya MitomaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki , Miyazaki, Japan.
Gideon SchreiberDepartment of Biomolecular Sciences, Weizmann Institute of Science , Rehovot, Israel.ORCID 0000-0002-2922-5882
Hiroyuki AsakuraTokyo Metropolitan Institute of Public Health , Tokyo, Japan.
Mami NagashimaTokyo Metropolitan Institute of Public Health , Tokyo, Japan.
Kenji SadamasuTokyo Metropolitan Institute of Public Health , Tokyo, Japan.
Kazuhisa YoshimuraTokyo Metropolitan Institute of Public Health , Tokyo, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University , Kyoto, Japan.
Genotype to Phenotype Japan (G2P-Japan) Consortium
Jumpei ItoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.
Kotaro ShirakawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University , Kyoto, Japan.ORCID 0000-0002-7469-1276
Kazuo TakayamaCenter for iPS Cell Research and Application (CiRA), Kyoto University , Kyoto, Japan.ORCID 0000-0002-1132-2457
Takashi IrieGraduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima, Japan.ORCID 0000-0003-3765-8482
Takao HashiguchiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University , Kyoto, Japan.ORCID 0000-0001-7578-7571
So NakagawaDepartment of Molecular Life Science, Tokai University School of Medicine , Isehara, Japan.ORCID 0000-0003-1760-3839
Takasuke FukuharaDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University , Sapporo, Japan.ORCID 0000-0001-5471-8331
Akatsuki SaitoDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki , Miyazaki, Japan.ORCID 0000-0002-2792-4399
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University , Kumamoto, Japan.ORCID 0000-0003-2869-9450
Kei SatoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan.ORCID 0000-0003-4431-1380
Kyoto University · JPTokyo University of Science · JPHokkaido University · JPKumamoto University · JPTokyo Metropolitan Institute of Public Health · JPUniversity of Miyazaki · JPThe University of Tokyo · JPHiroshima University · JPNational Institute of Infectious Diseases · JPCharles University · CZKobe University · JPKyushu University · JPNational Institute of Genetics · JPSapporo University · JPSuez Canal University · EGTokai University · JPWeizmann Institute of Science · IL
Funding
European Union, Next Generation EU LX22NPO5103International Joint Research Project of the Institute of Medical Science, the University of TokyoIntramural grant from Kumamoto University COVID-19 Research Projects (AMABIE)Ito Foundation Research GrantJapan Agency for Medical Research and Development (AMED) CREST JP21gm1610005Japan Agency for Medical Research and Development (AMED) CREST JP22gm1610008Japan Agency for Medical Research and Development (AMED) JP21fk0108425Japan Agency for Medical Research and Development (AMED) JP21fk0108432Japan Agency for Medical Research and Development (AMED) JP21fk0108465Japan Agency for Medical Research and Development (AMED) JP21fk0108493Japan Agency for Medical Research and Development (AMED) JP21fk0108494Japan Agency for Medical Research and Development (AMED) JP21fk0108574Japan Agency for Medical Research and Development (AMED) JP223fa627001Japan Agency for Medical Research and Development (AMED) JP223fa627009Japan Agency for Medical Research and Development (AMED) JP223fa727002Japan Agency for Medical Research and Development (AMED) JP22fk0108146Japan Agency for Medical Research and Development (AMED) JP22fk0108506Japan Agency for Medical Research and Development (AMED) JP22fk0108511Japan Agency for Medical Research and Development (AMED) JP22fk0108516Japan Agency for Medical Research and Development (AMED) JP22fk0108617Japan Agency for Medical Research and Development (AMED) JP22fk0410033Japan Agency for Medical Research and Development (AMED) JP22fk0410039Japan Agency for Medical Research and Development (AMED) JP22fk0410047Japan Agency for Medical Research and Development (AMED) JP22fk0410055Japan Agency for Medical Research and Development (AMED) JP22jk0210039Japan Agency for Medical Research and Development (AMED) JP22wm0325009Japan Agency for Medical Research and Development (AMED) JP23fk0410047Japan Agency for Medical Research and Development (AMED) JP23fk0410056Japan Agency for Medical Research and Development (AMED) JP23fk0410058Japan Science an Technology Agency (JST) CREST JPMJCR20H4Japan Science an Technology Agency (JST) CREST JPMJCR20H6Japan Science an Technology Agency (JST) CREST JPMJCR20H8Japan Science an Technology Agency (JST) PRESTO JPMJPR22R1Japan Science an Technology Agency (JST) SPRING JPMJSP2108Japan Society for the Promotion of Science (JSPS) DC2 22J11578Japan Society for the Promotion of Science (JSPS) JPJSCCA20190008Japan Society for the Promotion of Science (JSPS) JSPS Leading Initiative for Excellent Young Researchers (LEADER); number has not been assignedJapan Society for the Promotion of Science (JSPS) KAKENHI 20H05773Japan Society for the Promotion of Science (JSPS) KAKENHI 20K15767Japan Society for the Promotion of Science (JSPS) KAKENHI 21H02736Japan Society for the Promotion of Science (JSPS) KAKENHI 22K07103Japan Society for the Promotion of Science (JSPS) KAKENHI 22K16375Japan Society for the Promotion of Science (JSPS) KAKENHI 23K14526Mochida Memorial Foundation for Medical and Pharmaceutical ResearchNaito FoundationShin-Nihon Foundation of Advanced Medical ResearchTakeda Science FoundationWaksman Foundation of Japan
Abstract
importanceMost studies investigating the characteristics of emerging SARS-CoV-2 variants have been focusing on mutations in the spike proteins that affect viral infectivity, fusogenicity, and pathogenicity. However, few studies have addressed how naturally occurring mutations in the non-
Indexed as
Genome, ViralMutationSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19HumansSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BA.1BA.2COVID-19fusogenicitygrowth capacityimmune resistanceOmicronpathogenicitySARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.